PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held March 29 – April 3, 2019 in Atlanta, Georgia.

Poster Presentation 1
Title: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
Presenter: J. Randolph Hecht M.D., UCLA
Session: Phase I Clinical Trials: Part 1
Abstract Number: CT007
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Date and Time: Sunday, March 31, 2019 1:00 p.m. - 5:00 p.m. ET

Poster Presentation 2
Title: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients
Presenter: Mark N. Stein M.D., FACS, Columbia University, NYC
Session: Phase I Clinical Trials: Part 3
Abstract Number: CT098
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Date and Time: Monday, April 1, 2019 1:00 p.m. - 5:00 p.m. ET

All accepted abstracts will be published in the 2019 Proceedings of the AACR. Session information is available online via the Annual Meeting Itinerary Planner through the AACR website at www.aacr.org.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors. Advaxis has four programs in various stages of clinical development: ADXS-HPV for cervical cancer; ADXS-NEO, a personalized neoantigen-directed therapy for multiple cancers; ADXS-503 for non-small cell lung cancer, from its ADXS-HOT off-the-shelf neoantigen-directed program; and ADXS-PSA for prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

CONTACT:

Investors:
LHA Investor Relations
Miriam Weber Miller, (212) 838-3777
mmiller@lhai.com